Looking for a solution to accelerate your drug discovery processes? Introducing WuXi AppTec’s Integrated Direct-to-Biology (D2B) platform—a cost-effective and time-saving...

We are excited to announce the official launch of WuXi Biology HTS Platform 2.0, an advanced platform designed to enhance...

[Detection Antibodies + Target Development + High-Standard Controls] Empowering the Entire Drug Development Verification Process: In 2024 the OncoWuXi database...

WuXi AppTec has received Scientist.com’s Supplier Recognition Award for outstanding performance in offering drug discovery research services on their R&D...

At Biotech Showcase 2025, our co-CEO, Dr. Steve Yang, was interviewed by Informa Life Sciences. In this engaging interview, Dr....

Season’s Greetings from WuXi AppTec Dear customers and friends, As 2024 comes to a close, I hope you and your...

WuXi Biology has launched an upgraded edition of its DNA-encoded library kit – “DEL SE 2.0”. This enhanced version significantly...

From Tumor Model Database to Comprehensive Pharmacology Database: The OncoWuXi database has successfully upgraded to version 3.0, marking a significant...

We are excited to announce that Crelux, the structure-based drug discovery specialists of WuXi AppTec Discovery Biology, is relocating its...